Strong fondaparinux sales: Alchemia

Reported by AAP
Monday, February 6, 2012

Currency Converter

altTax Time 2011Doing your tax doesn't need to be daunting! Check out ninemsn Finance's Tax Time for tips and advice on how to make your 2011/12 tax return work for you.

Drug developer Alchemia Ltd says sales of its lead drug, generic fondaparinux, have been strong.

Fondaparinux is a generic version of GlaxoSmithKline's Arixtra, a synthetic anticoagulant mainly used for the prevention of deep vein thrombosis.

Generic fondaparinux was launched in July 2011 in the United States by Alchemia's marketing partner Dr Reddy's Laboratories.

Alchemia on Monday said the latest weekly data from pharmaceutical intelligence provider IMS Health showed that Dr Reddy's generic fondaparinux reported prescription market share of 18 per cent, or more than $US1.4 million in sales per week.

"We are very happy with the advances made by Dr Reddy's, both in terms of the market share achieved and the increases in yields and production capacity," Alchemia chief executive Pete Smith said in a statement.

"With this strong performance, we believe that we are on track to meet our expectations for fondaparinux in 2012."

Shares in Alchemia were 3.5 Australian cents, or 10.61 per cent, higher at 36.5 cents at 1349 AEDT on Monday.

21/05/2012 23:24Sydney, Australia. 21 May,2012
advertisement

Most Recommended